REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 222 filers reported holding REATA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $682,000 | +96.0% | 20,815 | +746.5% | 0.05% | +47.1% |
Q2 2021 | $348,000 | -69.8% | 2,459 | -56.4% | 0.03% | -69.6% |
Q4 2019 | $1,152,000 | +102.5% | 5,634 | -20.5% | 0.11% | +154.5% |
Q3 2019 | $569,000 | +1.1% | 7,085 | +7.5% | 0.04% | +37.5% |
Q1 2019 | $563,000 | – | 6,591 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $94,902,000 | 15.92% |
Opaleye Management Inc. | 407,002 | $13,333,000 | 4.14% |
Ikarian Capital, LLC | 649,600 | $21,281,000 | 2.80% |
AWH Capital, L.P. | 150,000 | $2,459,457 | 2.54% |
Boxer Capital, LLC | 1,239,000 | $40,590,000 | 2.09% |
EcoR1 Capital, LLC | 1,975,611 | $64,721,000 | 2.02% |
Camber Capital Management LP | 1,500,000 | $49,140,000 | 1.78% |
MPM BioImpact LLC | 180,000 | $5,897,000 | 1.58% |
Sofinnova Investments, Inc. | 602,545 | $19,739,000 | 1.50% |
KRS Capital Management, LLC | 28,141 | $921,000 | 1.00% |